non-small-cell lung cancer
Conditions
Interventions
No intervention group:Routine pharmaceutical care was performed using the pharmaceutical care essentials recommended in the Guidelines on Whole-process Pharmaceutical Care for Immunocheckpoint inhibit
intervention group:Routine pharmaceutical care was carried out according to the recommended pharmaceutical care points of the Guidelines on Whole-process Pharmaceutical Care for Immunocheckpoint inhib
Sponsors
Shanghai Changhai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Real world patients in relevant departments of each center, aged from 18 to 80 years old, male or female; (2) in accordance with para bead sheet resistance to isle of non-small cell lung cancer indications (epidermal growth factor receptor gene mutation invisible and anaplastic lymphoma kinase negative metastatic squamous non-small cell lung cancer, TPS of 1% or more negative epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase negative locally advanced or metastatic non-small cell lung cancer and metastatic squamous non-small cell lung cancer), choose with palmer show bead resistance to treatment of patients with clinical; (3) Volunteered to participate in this clinical study, willing to cooperate with the requirements of this project for TDM monitoring, and signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) Allergic to the active ingredients or excipients contained in this product; (2) Patients with off-label indications using this product; (3) Metastatic patients with active tumors in the central nervous system; (4) Those whose ECOG PS score is above 3; (5) HIV, HBV, HCV and other infected persons; (6) Patients with active systemic autoimmune diseases; (7) Patients with interstitial lung disease; (8) Pneumonia patients who have previously required systemic corticosteroid therapy; (9) A history of severe allergy or immune-related adverse reaction to another monoclonal antibody; (10) those who have used systemic antibiotics in the past 1 month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of immune-related adverse reactions; | — |
Countries
China
Contacts
Public ContactWang Zhuo
Shanghai Changhai Hospital
Outcome results
None listed